Luxa Biotechnology is a clinical-stage biotechnology firm developing a unique adult RPE stem cell (RPESC) therapy for dry AMD.
Luxa Biotechnology has raised $4.0M in total funding. The most recent round was Grant. The last funding was announced in May 2024.
Luxa Biotechnology's investors include California Institute for Regenerative Medicine.
Luxa Biotechnology is headquartered in Fort Lee, United States.
Luxa Biotechnology is a clinical-stage biotechnology firm developing a unique adult RPE stem cell (RPESC) therapy for dry AMD.
Luxa Biotechnology is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Luxa Biotechnology — Funding & Investors." VCBacked, May 1, 2024, https://www.vcbacked.co/company/luxa-biotechnology. Accessed August 14, 2026.
VCBacked. (2024). Luxa Biotechnology — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/luxa-biotechnology
{{cite web |title=Luxa Biotechnology — Funding & Investors |url=https://www.vcbacked.co/company/luxa-biotechnology |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated